Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Asciminib in chronic myeloid leukemia.
Assanto GM, Scalzulli E, Breccia M. Assanto GM, et al. Among authors: scalzulli e. Drugs Today (Barc). 2022 Oct;58(10):479-489. doi: 10.1358/dot.2022.58.10.3441853. Drugs Today (Barc). 2022. PMID: 36305542 Review.
The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?
Iori AP, Breccia M, Girmenia C, Perrone S, Valle V, Natalino F, Barberi W, Scalzulli E, Torelli GF, Puzzolo MC, Foà R. Iori AP, et al. Among authors: scalzulli e. Leuk Lymphoma. 2013 Mar;54(3):669-70. doi: 10.3109/10428194.2012.715348. Epub 2012 Oct 4. Leuk Lymphoma. 2013. PMID: 23036078 No abstract available.
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.
Breccia M, Colafigli G, Molica M, Scalzulli E, Diverio D, Latagliata R, Guarini A, Foà R. Breccia M, et al. Among authors: scalzulli e. Am J Hematol. 2017 Dec;92(12):E668-E670. doi: 10.1002/ajh.24916. Epub 2017 Oct 19. Am J Hematol. 2017. PMID: 28960424 Free article. No abstract available.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M. Caocci G, et al. Among authors: scalzulli e. Hematol Oncol. 2019 Aug;37(3):296-302. doi: 10.1002/hon.2606. Epub 2019 Apr 17. Hematol Oncol. 2019. PMID: 30892724 Free PMC article.
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.
Caocci G, Mulas O, Bonifacio M, Abruzzese E, Galimberti S, Orlandi EM, Iurlo A, Annunziata M, Luciano L, Castagnetti F, Gozzini A, Stagno F, Binotto G, Pregno P, Albano F, Martino B, Fozza C, Scaffidi L, Trawinska MM, Baratè C, Elena C, Cattaneo D, Scalzulli E, La Nasa G, Foà R, Breccia M. Caocci G, et al. Among authors: scalzulli e. Int J Cardiol. 2019 Aug 1;288:124-127. doi: 10.1016/j.ijcard.2019.04.051. Epub 2019 Apr 17. Int J Cardiol. 2019. PMID: 31029498
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
Breccia M, Luciano L, Pugliese N, Rossi E, Tiribelli M, Scalzulli E, Bonifacio M, Martino B, Latagliata R, Benevolo G, Caocci G, Binotto G, Martinelli V, Cavo M, Pane F, De Stefano V, Foà R, Palandri F. Breccia M, et al. Among authors: scalzulli e. Ann Hematol. 2019 Aug;98(8):1933-1936. doi: 10.1007/s00277-019-03727-6. Epub 2019 Jun 14. Ann Hematol. 2019. PMID: 31201513
70 results